XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre-Clinical Program in Hepatitis C to Presidio
More News related to BMY
- Asterand Announces Extension of Agreement with Bristol-Myers Squibb
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
- Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
- Bristol-Myers (BMY) To Spin-Off Mead Johnson (MJN) Holdings
More News related to XTLB
- XTL Biopharmaceuticals (XTLB) Slashes 75% of Workforce
- Unusual 11 Mid-Day Movers 11/18: IDMI, PSUN, DHT, CQB Higher; XTLB, NCOC, SKS, DIVX Lower
- Ladenburg Thalmann Downgrades XTL Biopharmaceuticals (XTLB) to Sell
- Pre-Open Movers: Winnebago (WGO) Sinks On Poor Results, Borders (BGP) Up On Earnings/Strategic Review
- XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre-Clinical Program in Hepatitis C to Presidio
More News related to Corporate News
- S&P lowers Ciena (CIEN) corporate credit rating from B+ to B
- comScore (SCOR) Sees 3% Growth in '09 Holiday E-Commerce Spending
- Agrium (AGU) Acquires 24 Retail Props from Agriliance
- Highlights From HNZ's Q2 Conference Call: Continued Growth Overseas; Guides Higher for FY10
- ECB said to debate putting adjustable rate on 12-month loans
XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) announced the licensing of its pre-clinical program in Hepatitis C focused on the NS5A target to San-Francisco based Presidio Pharmaceuticals, Inc. Presidio is a private biotechnology company focused on the development and commercialization of anti-viral therapeutics.
Presidio's scientific team is headed by Dr. Richard Colonno, who until recently was Vice President of Infectious Disease Drug Discovery at Bristol-Myers Squibb (NYSE: BMY), where he was responsible for Bristol-Myers Squibb's antiviral drug discovery efforts, including their Hepatitis C and B and HIV programs.
Under the license agreement, Presidio becomes responsible for all further development and commercialization activities and costs relating to the Program. XTL will receive an upfront payment of $4 million, and up to an additional $104 million upon reaching certain development and commercialization milestones. In addition, XTL will receive a royalty on direct product sales by Presidio, and a percentage of Presidio's income if the Program is sublicensed by Presidio to a third party.[SM]
Related Categories
Corporate NewsStocks Mentioned
-0.11
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
